[{"address1": "321 Harrison Avenue", "address2": "11th Floor, Suite 1", "city": "Boston", "state": "MA", "zip": "02118", "country": "United States", "phone": "617 453 3596", "website": "https://www.pyxisoncology.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 44, "companyOfficers": [{"maxAge": 1, "name": "Dr. Lara S. Sullivan M.D., MBA", "title": "CEO, President, Chief Medical Officer & Director", "fiscalYear": 2024, "totalPay": 1057225, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jitendra  Wadhane C.A., CPA", "age": 45, "title": "Chief Accounting Officer, Senior VP of Finance, Corporate Controller & Principal Financial Officer", "yearBorn": 1980, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Balu N. Balasubramanian Ph.D.", "title": "Interim Chief Technology Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jan  Pinkas Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alex  Kane M.B.A.", "title": "Senior Vice President of Investor Relations & Capital Markets", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Donna  Regalado", "title": "Head of Human Resources", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Charles T. Gombar Ph.D.", "title": "Senior Vice President of Portfolio & Program Management", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen T. Worsley MBA", "age": 61, "title": "Senior VP & Chief Business Officer", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael  Bui", "title": "Head of Global Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Supriya  Roth Ph.D.", "title": "Head of Commercial Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.71, "open": 1.71, "dayLow": 1.6, "dayHigh": 1.71, "regularMarketPreviousClose": 1.71, "regularMarketOpen": 1.71, "regularMarketDayLow": 1.6, "regularMarketDayHigh": 1.71, "payoutRatio": 0.0, "beta": 1.451, "forwardPE": -1.3842888, "volume": 359806, "regularMarketVolume": 359806, "averageVolume": 1317450, "averageVolume10days": 1695790, "averageDailyVolume10Day": 1695790, "bid": 1.21, "ask": 2.08, "bidSize": 2, "askSize": 2, "marketCap": 101490672, "fiftyTwoWeekLow": 0.833, "fiftyTwoWeekHigh": 5.55, "allTimeHigh": 19.0, "allTimeLow": 0.833, "priceToSalesTrailing12Months": 35.9896, "fiftyDayAverage": 3.0357, "twoHundredDayAverage": 2.037475, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 44307672, "profitMargins": 0.0, "floatShares": 41286156, "sharesOutstanding": 62264215, "sharesShort": 1733403, "sharesShortPriorMonth": 4523744, "sharesShortPreviousMonthDate": 1764288000, "dateShortInterest": 1767139200, "sharesPercentSharesOut": 0.0278, "heldPercentInsiders": 0.22662, "heldPercentInstitutions": 0.39481, "shortRatio": 0.97, "shortPercentOfFloat": 0.0337, "impliedSharesOutstanding": 62264215, "bookValue": 1.107, "priceToBook": 1.4724481, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -97086000, "trailingEps": -1.58, "forwardEps": -1.1775, "enterpriseToRevenue": 15.712, "enterpriseToEbitda": -0.551, "52WeekChange": 0.03821659, "SandP52WeekChange": 0.15024745, "quoteType": "EQUITY", "currentPrice": 1.63, "targetHighPrice": 9.0, "targetLowPrice": 5.0, "targetMeanPrice": 7.175, "targetMedianPrice": 7.2, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 76256000, "totalCashPerShare": 1.225, "ebitda": -80469000, "totalDebt": 19073000, "quickRatio": 3.934, "currentRatio": 4.286, "totalRevenue": 2820000, "debtToEquity": 27.731, "revenuePerShare": 0.046, "returnOnAssets": -0.34326, "returnOnEquity": -0.87284, "grossProfits": 2820000, "freeCashflow": -40940624, "operatingCashflow": -72365000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -29.30248, "financialCurrency": "USD", "symbol": "PYXS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1633699800000, "postMarketChangePercent": -1.2269927, "postMarketPrice": 1.61, "postMarketChange": -0.01999998, "regularMarketChange": -0.08, "regularMarketDayRange": "1.6 - 1.71", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1317450, "fiftyTwoWeekLowChange": 0.797, "fiftyTwoWeekLowChangePercent": 0.9567827, "fiftyTwoWeekRange": "0.833 - 5.55", "fiftyTwoWeekHighChange": -3.92, "fiftyTwoWeekHighChangePercent": -0.7063063, "fiftyTwoWeekChangePercent": 3.821659, "earningsTimestamp": 1762176600, "earningsTimestampStart": 1762176600, "earningsTimestampEnd": 1762176600, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -1.58, "epsForward": -1.1775, "epsCurrentYear": -1.30111, "priceEpsCurrentYear": -1.2527764, "marketState": "CLOSED", "shortName": "Pyxis Oncology, Inc.", "longName": "Pyxis Oncology, Inc.", "regularMarketChangePercent": -4.67836, "regularMarketPrice": 1.63, "fiftyDayAverageChange": -1.4057001, "fiftyDayAverageChangePercent": -0.46305633, "twoHundredDayAverageChange": -0.4074751, "twoHundredDayAverageChangePercent": -0.19999023, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-10-08", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "exchange": "NMS", "messageBoardId": "finmb_629268721", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "postMarketTime": 1769213766, "regularMarketTime": 1769202000, "displayName": "Pyxis Oncology", "trailingPegRatio": null, "__fetch_time": "2026-01-24"}]